Blogs

Categories

Select a Sub-Category

Films and Coatings
Pharmaceutical Packaging Components
Prefillable Systems
Self Injection Devices
Vial Containment Solutions
Washing and Sterilization
Reconstitution and Transfer Devices

Select a Sub-Category

Analytical Lab Services
Contract Manufacturing
Fill-Finish
Regulatory Support

Select a Sub-Category

Cell and Gene Therapy Packaging
Drug Development Process
Regulatory Challenges
Transitioning to Combination Products

Select a Sub-Category

Corporate Development
ESG/Sustainability
One West Team (Employee Culture)
Our Culture of Giving (Philanthropy)
Research and Development

Previous Blogs

A girl Smiling with her dog

By West's Marketing Team

七月 30, 2018

Elemental impurities, such as arsenic, cadmium, lead and mercury are ubiquitous in nature. They are also toxic to humans and animals at certain levels. Because these elements are often part of mined minerals used in the manufacture of drug products and/or drug containment systems, they can have an impact on the quality of a drug.

Scientist performing tests in a lab

By Jennifer Riter

一月 12, 2018

On January 1, 2018, new USP standards became mandatory for measuring elemental impurities in pharmaceuticals and their ingredients – aligning with ICH Q3D, which provides limits for the amount of elemental impurities in drug products. New USP General Chapters, USP <232> (Elemental Impurities – Limits) and USP <233> (Elemental Impurities – Procedures) have replaced USP <231> (Heavy Metals). USP <231>, which historically was used to test for heavy metals in drug products as well as packaging components, has been withdrawn. However, the heavy metals testing in USP <381> (Elastomeric Closure for Injections), which is used for testing of elastomeric closures, still references USP <231>.

Scientist performing tests in laboratory

By Diego Zurbriggen

一月 09, 2018

Material characterization is an important part of the selection process of containment/delivery systems for parenteral drug products.